Frontier Group Q2 revenue beats estimates on travel demand
Reuters2026/07/29 12:09
Overview
U.S. low-cost airline's Q2 revenue rose 38% yr/yr, beating analyst expectations
Adjusted Q2 loss per share and adjusted net loss both beat analyst expectations
Company cites strong travel demand and commercial strategy for revenue growth
Outlook
Frontier sees Q3 adjusted diluted EPS between $(0.10) and $0.10
Company expects Q3 capacity growth of 17-18% versus prior-year qtr
Frontier expects full-year pre-delivery deposit balance to decrease by $170-$210 mln
Result Drivers
TRAVEL DEMAND - Co said record Q2 revenue was driven by strong travel demand and favorable competitive capacity
REVENUE MANAGEMENT - Revenue management initiatives and commercial strategy contributed to higher RASM and revenue growth
NETWORK EXPANSION - Expanded network across key leisure and business markets supported revenue growth
Company press release: ID:nPn1GBt7ra
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Operating revenue |
Beat |
$1.28 bln |
$1.22 bln (8 Analysts) |
Q2 Adjusted Loss Per Share |
Beat |
$0.10 |
$0.48 (10 Analysts) |
Q2 Adjusted Net Loss |
Beat |
$22 mln |
$111.55 mln (8 Analysts) |
Q2 Net Loss |
|
$90 mln |
|
Q2 Adjusted Pretax Loss |
Beat |
$24 mln |
$115.80 mln (7 Analysts) |
Q2 Pretax Loss |
|
$94 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 9 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the airlines peer group is "buy."
Wall Street's median 12-month price target for Frontier Group Holdings Inc is $7.00, about 12.4% above its July 28 closing price of $6.23
Reuters Recommended Reads
July 28 - JetBlue recaptures nearly half of fuel cost surge, beats Street estimates
July 29 - Resilient tourists help US travel firms absorb Middle East shock
July 28 - Singapore Airlines posts first quarterly loss since 2022
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street -- WSJ
NASDAQ TRADE HALT CONTINUES <EFTY.O> REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 03:28 AM